Tag: Active metabolite of venlafaxine (SNRI)

  • Desvenlafaxine

    Active metabolite of venlafaxine (SNRI)

    The major active metabolite of venlafaxine; a pure SNRI marketed separately to bypass CYP2D6 polymorphism.

    Abstract

    Desvenlafaxine (4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol; CAS 93413-62-8; molecular formula C16H25NO2; molecular weight 263.38) is the O-desmethylated active metabolite of venlafaxine, marketed as Pristiq by Wyeth/Pfizer after FDA approval in 2008. The compound is a structurally similar SNRI to venlafaxine with comparable SERT (Ki approximately 40 nM) and NET (Ki approximately 558 nM) affinity but a more balanced ratio than the parent compound, producing meaningful NET inhibition at lower doses. The principal pharmacokinetic advantage is bypass of CYP2D6 metabolism: desvenlafaxine is conjugated and excreted directly without further hepatic transformation, producing flat steady-state concentrations across CYP2D6 phenotypes and minimal drug-drug interaction potential. Discontinuation syndrome is comparable to venlafaxine. Used as a reference SNRI compound when CYP2D6 variability is undesirable.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.